Local treatment for HER2-positive or triple negative second ipsilateral breast cancer event: A propensity score-matched analysis of the GEC-ESTRO database
Open Access
- 11 August 2026
- journal article
- Published by Elsevier in The Breast
- Vol. 89, 104895
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensusThe Lancet Oncology, 2026
- Local management of second breast cancer event after primary breast conserving therapy: The patient's perspectiveEuropean Journal of Surgical Oncology, 2025
- Salvage Therapy for Isolated Local-Regional Breast Cancer RecurrenceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2025
- Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trialThe Lancet Oncology, 2025
- Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice GuidelinePractical Radiation Oncology, 2023
- Second Conservative Treatment for Local Recurrence Breast Cancer: A GEC-ESTRO Oncological Outcome and Prognostic Factor AnalysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
- European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision makingThe Lancet Oncology, 2022
- Partial breast irradiation: An updated consensus statement from the American brachytherapy societyBrachytherapy, 2022
- Salvage Mastectomy Versus Second Conservative Treatment for Second Ipsilateral Breast Tumor Event: A Propensity Score-Matched Cohort Analysis of the GEC-ESTRO Breast Cancer Working Group DatabaseInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trialThe Lancet, 2020